The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
A Nationwide Survey of Mortality in Acromegaly
Abstract
CONTEXT: Increased mortality in acromegaly has been confined to those with posttreatment basal GH of 2.5 microg/liter or greater, but the impact of IGF-I and pituitary radiotherapy on mortality has remained controversial. OBJECTIVE: The purpose of this nationwide survey was to examine the all-cause mortality of patients with acromegaly and evaluate the impact of treatment outcome and mode of treatment on survival. DESIGN, SETTING, AND PATIENTS: All-cause mortality of all patients with acromegaly diagnosed during January 1980 and December 1999 in the five university hospitals of Finland was followed up by the end of 2002 (12.5 +/- 5.6 yr) and compared with that of the general population by using age- and gender-adjusted standardized mortality ratios (SMRs). Logistic regression analysis was used to investigate factors related to mortality within the survey population. MAIN OUTCOME MEASURE: Mortality was the main outcome measure. RESULTS: Of the 334 patients, 56 (16.8%) had died during follow-up. SMR of the patients was 1.16 [confidence interval (CI) 0.85-1.54, not significant (NS)]. However, patients with basal serum GH concentration 2.5 microg/liter or greater (SMR 1.63, CI 1.10-2.35, P < 0.001) measured 5.2 +/- 4.4 yr after the initial treatment, and those irradiated (SMR 1.69, CI 1.05-2.58, P < 0.001) showed excess mortality. In a multivariate model, the effect of radiotherapy was of borderline significance only (P = 0.083). Posttreatment IGF-I levels, available for 72.2% of the patients, did not have impact on mortality. CONCLUSIONS: The posttreatment basal GH concentration less than 2.5 microg/liter in acromegalic patients is associated with a normal lifespan. Excess mortality is confined to poorly controlled patients and possibly those who have received conventional radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Factors Influencing Mortality in Acromegaly
Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031199 · Cited by 651
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Wright, A. D., Hill, D. M., Lowy, C., & Fraser, T. R. (1970) · PubMed · Cited by 529
BENGTSSON, B., EDÉN, S., ERNEST, I., ODÉN, A., & SJÖGREN, B. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15881.x · Cited by 528
EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION
ALEXANDER, L., APPLETON, D., HALL, R., ROSS, W. M., & WILKINSON, R. (1980) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1980.tb03135.x · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510439 · Cited by 387
Abosch, A., Tyrrell, J. B., Lamborn, K. R., Hannegan, L. T., Applebury, C. B., & Wilson, C. B. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3411 · Cited by 361
Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031584 · Cited by 343
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Biermasz, N. R., Dekker, F. W., Pereira, A. M., van Thiel, S. W., Schutte, P. J., van Dulken, H., Romijn, J. A., & Roelfsema, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032041 · Cited by 193
Statistical methods in cancer research
Simpson, P. M., Spratt, J. A., & Spratt, J. S. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1035 · Cited by 124
COLON CANCER AND POLYPS IN ACROMEGALY: INCREASED RISK ASSOCIATED WITH FAMILY HISTORY OF COLON CANCER
BRUNNER, J. E., Johnson, C. C., Zafar, S. U., Peterson, E. L., BRUNNER, J. F., & Mellinger, R. C. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb03751.x · Cited by 106
Risk Factors for Cerebrovascular Deaths in Patients Operated and Irradiated for Pituitary Tumors
Erfurth, E. M., Bülow, B., Svahn‐Tapper, G., Norrving, B. G., Odh, K., Mikoczy, Z., Björk, J., & Hagmar, L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020526 · Cited by 103
Seth, J., Ellis, A. R., & Al-Sadie, R. (1999) · Hormone Research in Paediatrics · doi:10.1159/000053130 · Cited by 46
Mortality in 154 Surgically Treated Patients with Acromegaly-A 10-year Follow-Up Survey
Arita, K., Kurisu, K., Tominaga, A., Eguchi, K., Iida, K., Uozumi, T., & Kasagi, F. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.163 · Cited by 42
Cited by
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Melmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene
Vierimaa, O., Georgitsi, M., Lehtonen, R., Vahteristo, P., Kokko, A., Raitila, A., Tuppurainen, K., Ebeling, T. M. L., Salmela, P. I., Paschke, R., et al. (2006) · Science · doi:10.1126/science.1126100 · Cited by 618
Self-citation
Metadata
- Authors
- Kauppinen-Mäkelin, R., Sane, T., Reunanen, A., Välimäki, M. J., Niskanen, L., Markkanen, H., Löyttyniemi, E., Ebeling, T., Jaatinen, P., Laine, H., Nuutila, P., Salmela, P., Salmi, J., Stenman, U.-H., Viikari, J., & Voutilainen, E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-07
- Volume
- 90
- Issue
- 7
- Pages
- 4081-4086
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2157482119
- Cited by
- 269
- References
- 21
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.